Alivus Life Sciences Ltd · ALIVUS · Pharmaceuticals Bulk Drugs & Formulation · price as of the 20 November 2026 close, updated every trading day · results updated weekly · research updated 30 October 2026
Alivus Life Sciences share price today: ₹1,436.90 at the close on 20 November 2026, up 59.0% in a year. Alivus Life Sciences (ALIVUS) is worth ₹17,665 crore, trades at a P/E of 26.3 and has closed between ₹880.15 and ₹1,558.70 over the past 52 weeks. Latest change: best operating margin in 16 quarters.
Alivus Life Sciences Ltd's share price has risen faster than its earnings: +59.0% in a year, against +26.1% for earnings per share.
The main question: the share price moved +59.0% in a year while earnings per share (last four quarters) moved +26.1%. The difference came from the market paying a higher multiple.
The price has been rising for 31 weeks, and the P/E is higher than 81% of its own last 5.3 years. Over the last four quarters, results have been improving, with profit +51.5% on a year earlier, and 90% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
Our full read on Alivus Life Sciences, including whether management kept its promises and what could stop it, is in the Sector Alpha newsletter.
What is the Alivus Life Sciences share price today?
Alivus Life Sciences Ltd's share price was ₹1,436.90 at the close on 20 November 2026. It has been rising for 31 weeks. That is 19.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹880 and ₹1,559, and at that close it sat 82% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Alivus Life Sciences Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 26 weeks in a row.
Week by week since 2021: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 130 of 272 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 6 Aug 2021 | no NIFTY 500 reading |
| 13 Aug 2021 | no NIFTY 500 reading |
| 20 Aug 2021 | no NIFTY 500 reading |
| 27 Aug 2021 | no NIFTY 500 reading |
| 3 Sep 2021 | no NIFTY 500 reading |
| 9 Sep 2021 | no NIFTY 500 reading |
| 17 Sep 2021 | no NIFTY 500 reading |
| 24 Sep 2021 | no NIFTY 500 reading |
| 1 Oct 2021 | no NIFTY 500 reading |
| 8 Oct 2021 | no NIFTY 500 reading |
| 14 Oct 2021 | no NIFTY 500 reading |
| 22 Oct 2021 | no NIFTY 500 reading |
| 29 Oct 2021 | no NIFTY 500 reading |
| 4 Nov 2021 | −25.9% |
| 12 Nov 2021 | −25.5% |
| 18 Nov 2021 | −21.6% |
| 26 Nov 2021 | −10.2% |
| 3 Dec 2021 | −11.1% |
| 10 Dec 2021 | −9.1% |
| 17 Dec 2021 | −9.8% |
| 24 Dec 2021 | −8.2% |
| 31 Dec 2021 | −6.2% |
| 7 Jan 2022 | −9.3% |
| 14 Jan 2022 | −8.5% |
| 21 Jan 2022 | −2.6% |
| 28 Jan 2022 | −7.1% |
| 4 Feb 2022 | −8.0% |
| 11 Feb 2022 | −11.5% |
| 18 Feb 2022 | −13.2% |
| 25 Feb 2022 | −21.9% |
| 4 Mar 2022 | −18.7% |
| 11 Mar 2022 | −15.8% |
| 17 Mar 2022 | −24.2% |
| 25 Mar 2022 | −18.2% |
| 1 Apr 2022 | −24.8% |
| 8 Apr 2022 | −16.3% |
| 13 Apr 2022 | −14.5% |
| 22 Apr 2022 | −14.0% |
| 29 Apr 2022 | −17.3% |
| 6 May 2022 | −13.4% |
| 13 May 2022 | −10.2% |
| 20 May 2022 | −8.3% |
| 27 May 2022 | −7.5% |
| 3 Jun 2022 | −4.4% |
| 10 Jun 2022 | +0.3% |
| 17 Jun 2022 | +7.4% |
| 24 Jun 2022 | −1.7% |
| 1 Jul 2022 | +3.7% |
| 8 Jul 2022 | +2.8% |
| 15 Jul 2022 | +3.0% |
| 22 Jul 2022 | −2.8% |
| 29 Jul 2022 | −1.6% |
| 5 Aug 2022 | −7.0% |
| 12 Aug 2022 | −12.1% |
| 19 Aug 2022 | −11.2% |
| 26 Aug 2022 | −5.1% |
| 2 Sep 2022 | −7.6% |
| 9 Sep 2022 | −18.9% |
| 16 Sep 2022 | −22.5% |
| 23 Sep 2022 | −20.2% |
| 30 Sep 2022 | −23.5% |
| 7 Oct 2022 | −28.3% |
| 14 Oct 2022 | −20.0% |
| 21 Oct 2022 | −17.6% |
| 28 Oct 2022 | −13.6% |
| 4 Nov 2022 | −6.2% |
| 11 Nov 2022 | −5.7% |
| 18 Nov 2022 | −6.2% |
| 25 Nov 2022 | −7.6% |
| 2 Dec 2022 | −6.6% |
| 9 Dec 2022 | −4.2% |
| 16 Dec 2022 | −0.6% |
| 23 Dec 2022 | +0.8% |
| 30 Dec 2022 | +4.7% |
| 6 Jan 2023 | +9.3% |
| 13 Jan 2023 | −2.0% |
| 20 Jan 2023 | −3.7% |
| 27 Jan 2023 | −4.8% |
| 3 Feb 2023 | −10.9% |
| 10 Feb 2023 | −7.3% |
| 17 Feb 2023 | −5.9% |
| 24 Feb 2023 | −3.3% |
| 3 Mar 2023 | −3.8% |
| 10 Mar 2023 | −1.3% |
| 17 Mar 2023 | +2.9% |
| 24 Mar 2023 | +0.2% |
| 31 Mar 2023 | −0.7% |
| 6 Apr 2023 | −0.2% |
| 13 Apr 2023 | +3.8% |
| 21 Apr 2023 | +18.5% |
| 28 Apr 2023 | +27.4% |
| 5 May 2023 | +35.4% |
| 12 May 2023 | +38.4% |
| 19 May 2023 | +35.0% |
| 26 May 2023 | +38.7% |
| 2 Jun 2023 | +35.7% |
| 9 Jun 2023 | +42.9% |
| 16 Jun 2023 | +35.9% |
| 23 Jun 2023 | +31.2% |
| 30 Jun 2023 | +32.0% |
| 7 Jul 2023 | +36.1% |
| 14 Jul 2023 | +30.8% |
| 21 Jul 2023 | +24.0% |
| 28 Jul 2023 | +19.6% |
| 4 Aug 2023 | +12.1% |
| 11 Aug 2023 | +11.7% |
| 18 Aug 2023 | +11.0% |
| 25 Aug 2023 | +6.1% |
| 1 Sep 2023 | +7.3% |
| 8 Sep 2023 | −3.5% |
| 15 Sep 2023 | −1.7% |
| 22 Sep 2023 | +7.1% |
| 29 Sep 2023 | +3.3% |
| 6 Oct 2023 | −0.6% |
| 13 Oct 2023 | +5.2% |
| 20 Oct 2023 | −3.7% |
| 27 Oct 2023 | −4.2% |
| 3 Nov 2023 | −2.9% |
| 12 Nov 2023 | −4.8% |
| 17 Nov 2023 | −5.7% |
| 24 Nov 2023 | −3.6% |
| 1 Dec 2023 | −5.3% |
| 8 Dec 2023 | −6.1% |
| 15 Dec 2023 | −10.3% |
| 22 Dec 2023 | −10.3% |
| 29 Dec 2023 | −6.0% |
| 5 Jan 2024 | −1.7% |
| 12 Jan 2024 | +0.2% |
| 20 Jan 2024 | +14.1% |
| 25 Jan 2024 | +17.9% |
| 2 Feb 2024 | +23.3% |
| 9 Feb 2024 | +22.2% |
| 16 Feb 2024 | +25.7% |
| 23 Feb 2024 | +22.7% |
| 2 Mar 2024 | +20.3% |
| 7 Mar 2024 | +11.3% |
| 15 Mar 2024 | +13.1% |
| 22 Mar 2024 | +11.9% |
| 28 Mar 2024 | +14.0% |
| 5 Apr 2024 | +11.4% |
| 12 Apr 2024 | +4.3% |
| 19 Apr 2024 | −3.5% |
| 26 Apr 2024 | −10.0% |
| 3 May 2024 | −10.0% |
| 10 May 2024 | −7.5% |
| 18 May 2024 | −10.8% |
| 24 May 2024 | −9.7% |
| 31 May 2024 | −4.7% |
| 7 Jun 2024 | +6.9% |
| 14 Jun 2024 | +3.4% |
| 21 Jun 2024 | −1.1% |
| 28 Jun 2024 | +0.5% |
| 5 Jul 2024 | +0.2% |
| 12 Jul 2024 | −6.5% |
| 19 Jul 2024 | −6.5% |
| 26 Jul 2024 | −7.4% |
| 2 Aug 2024 | −4.5% |
| 9 Aug 2024 | −1.5% |
| 16 Aug 2024 | +9.2% |
| 23 Aug 2024 | +15.7% |
| 30 Aug 2024 | +13.4% |
| 6 Sep 2024 | +24.7% |
| 13 Sep 2024 | +43.8% |
| 20 Sep 2024 | +30.0% |
| 27 Sep 2024 | +10.0% |
| 4 Oct 2024 | +24.4% |
| 11 Oct 2024 | +36.6% |
| 18 Oct 2024 | +30.8% |
| 25 Oct 2024 | +13.7% |
| 1 Nov 2024 | +20.8% |
| 8 Nov 2024 | +21.1% |
| 14 Nov 2024 | +15.7% |
| 22 Nov 2024 | +4.9% |
| 29 Nov 2024 | +7.4% |
| 6 Dec 2024 | −7.5% |
| 13 Dec 2024 | −18.9% |
| 20 Dec 2024 | −4.3% |
| 27 Dec 2024 | +4.2% |
| 3 Jan 2025 | −6.9% |
| 10 Jan 2025 | −6.5% |
| 17 Jan 2025 | +3.5% |
| 24 Jan 2025 | +27.7% |
| 1 Feb 2025 | +15.3% |
| 7 Feb 2025 | +16.1% |
| 14 Feb 2025 | −0.3% |
| 21 Feb 2025 | +4.1% |
| 28 Feb 2025 | −6.0% |
| 7 Mar 2025 | +14.4% |
| 13 Mar 2025 | +14.2% |
| 21 Mar 2025 | +13.3% |
| 28 Mar 2025 | +14.4% |
| 4 Apr 2025 | +5.4% |
| 11 Apr 2025 | +0.3% |
| 17 Apr 2025 | −8.8% |
| 25 Apr 2025 | −12.3% |
| 2 May 2025 | −7.7% |
| 9 May 2025 | −9.0% |
| 16 May 2025 | +1.9% |
| 23 May 2025 | −0.2% |
| 30 May 2025 | +2.9% |
| 6 Jun 2025 | −20.1% |
| 13 Jun 2025 | −14.5% |
| 20 Jun 2025 | −17.6% |
| 27 Jun 2025 | −18.1% |
| 4 Jul 2025 | −9.3% |
| 11 Jul 2025 | −7.1% |
| 18 Jul 2025 | −0.4% |
| 25 Jul 2025 | −6.1% |
| 1 Aug 2025 | −11.1% |
| 8 Aug 2025 | −19.7% |
| 14 Aug 2025 | −16.5% |
| 22 Aug 2025 | −14.1% |
| 29 Aug 2025 | −7.7% |
| 5 Sep 2025 | −6.8% |
| 12 Sep 2025 | −8.9% |
| 19 Sep 2025 | +3.0% |
| 26 Sep 2025 | −2.4% |
| 3 Oct 2025 | −8.1% |
| 10 Oct 2025 | −8.2% |
| 17 Oct 2025 | −14.1% |
| 24 Oct 2025 | −13.1% |
| 31 Oct 2025 | −14.2% |
| 7 Nov 2025 | −6.9% |
| 14 Nov 2025 | −9.3% |
| 21 Nov 2025 | −10.3% |
| 28 Nov 2025 | −11.4% |
| 5 Dec 2025 | −8.7% |
| 12 Dec 2025 | −7.5% |
| 19 Dec 2025 | −14.8% |
| 26 Dec 2025 | −8.1% |
| 2 Jan 2026 | −6.7% |
| 9 Jan 2026 | −6.3% |
| 16 Jan 2026 | −4.0% |
| 23 Jan 2026 | −0.3% |
| 1 Feb 2026 | +3.8% |
| 6 Feb 2026 | +2.3% |
| 13 Feb 2026 | +3.9% |
| 20 Feb 2026 | +2.4% |
| 27 Feb 2026 | +4.7% |
| 6 Mar 2026 | +9.2% |
| 13 Mar 2026 | +16.2% |
| 20 Mar 2026 | +15.4% |
| 27 Mar 2026 | +19.7% |
| 2 Apr 2026 | +21.5% |
| 10 Apr 2026 | +23.6% |
| 17 Apr 2026 | +23.8% |
| 24 Apr 2026 | +19.5% |
| 30 Apr 2026 | +15.2% |
| 8 May 2026 | +21.6% |
| 15 May 2026 | +16.9% |
| 22 May 2026 | +17.2% |
| 29 May 2026 | +18.0% |
| 4 Jun 2026 | +13.3% |
| 5 Jun 2026 | +4.2% |
| 9 Jun 2026 | +3.0% |
| 10 Jun 2026 | −2.4% |
| 12 Jun 2026 | −2.3% |
| 17 Jun 2026 | −3.1% |
| 19 Jun 2026 | −1.1% |
| 24 Jun 2026 | +3.9% |
| 25 Jun 2026 | +4.9% |
| 1 Jul 2026 | +0.5% |
| 3 Jul 2026 | +7.4% |
| 10 Jul 2026 | +8.6% |
| 17 Jul 2026 | +4.4% |
| 24 Jul 2026 | +4.3% |
| 31 Jul 2026 | +7.9% |
| 7 Aug 2026 | +23.6% |
| 14 Aug 2026 | +30.0% |
| 21 Aug 2026 | +25.1% |
| 28 Aug 2026 | +26.8% |
| 4 Sep 2026 | +27.2% |
| 11 Sep 2026 | +25.3% |
| 18 Sep 2026 | +30.3% |
| 25 Sep 2026 | +23.2% |
| 28 Sep 2026 | +18.9% |
| 1 Oct 2026 | +24.8% |
| 9 Oct 2026 | +23.3% |
| 16 Oct 2026 | +21.7% |
| 23 Oct 2026 | +16.5% |
| 30 Oct 2026 | +14.1% |
| 6 Nov 2026 | +7.4% |
| 8 Nov 2026 | +15.7% |
| 13 Nov 2026 | +7.3% |
| 20 Nov 2026 | +3.1% |
Over the last 5.3 years the share price moved +92% while the NIFTY 500 moved +70%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Alivus Life Sciences this quarter?
Three changes stood out: best operating margin in 16 quarters, revenue up on a year earlier for 8 quarters in a row and profit up on a year earlier for 8 quarters in a row.
Best operating margin in 16 quarters
Operating margin was 39% in the September 2026 quarter, against 30% a year earlier.
Revenue up on a year earlier for 8 quarters in a row
In the September 2026 quarter revenue was ₹682 crore, +16% on a year earlier.
Why: Revenue rose because the business outside GPL grew 20.8%, helped by new product launches and demand across Europe, Japan, North America and other markets.
Next results: check whether GPL volume picks up in the second half as management expects.
From the earnings call on 30 Oct 2026.
Profit up on a year earlier for 8 quarters in a row
In the September 2026 quarter profit was ₹197 crore, +51.5% on a year earlier.
What are Alivus Life Sciences' latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Alivus Life Sciences reported revenue of ₹682 crore, up 16.0% from ₹588 crore a year earlier, and a profit of ₹197 crore, up 51.5% from ₹130 crore.
Alivus Life Sciences results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹682 crore | ₹588 crore | +16.0% |
| Profit | ₹197 crore | ₹130 crore | +51.5% |
| Earnings per share | ₹16.03 | ₹10.60 | +51.2% |
| Operating margin | 38.9% | 30.4% | +8.5 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Alivus Life Sciences' management discussed these results on a call held on 30 October 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Alivus Life Sciences share price history?
Alivus Life Sciences closed at ₹1,436.90 on 20 November 2026, up 59.0% from ₹903.85 a year earlier (21 November 2025) and up 129.5% over five years. Its highest weekly close since August 2021 was ₹1,558.70 on 8 November 2026.
Alivus Life Sciences share price: then and now
| When | Close | Change to 20 Nov 2026 |
|---|---|---|
| 1 week ago · 13 Nov 2026 | ₹1,460.60 | −1.6% |
| 1 month ago · 19 Oct 2026 | ₹1,268.60 | +13.3% |
| 6 months ago · 22 May 2026 | ₹1,039.00 | +38.3% |
| 1 year ago · 21 Nov 2025 | ₹903.85 | +59.0% |
| 3 years ago · 17 Nov 2023 | ₹626.35 | +129.4% |
| 5 years ago · 18 Nov 2021 | ₹626.05 | +129.5% |
| Earliest weekly close in our records · 6 Aug 2021 | ₹748.50 | +92.0% |
| Highest weekly close since August 2021, also the 52-week high · 8 Nov 2026 | ₹1,558.70 | −7.8% |
| Lowest weekly close since August 2021 · 3 Feb 2023 | ₹376.30 | +281.8% |
| 52-week low (weekly close) · 9 Jan 2026 | ₹880.15 | +63.3% |
Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
285 weekly closes from 6 August 2021 to 20 November 2026.
What is the latest news on Alivus Life Sciences?
20 Nov 2026: Alivus Life Sciences closed at ₹1,436.90, down 1.6% on the week and up 13.3% on the month. 30 Oct 2026: Alivus Life Sciences held its results call for July to September 2026. Management guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction.
Earlier
- Results for July to September 2026: Revenue up 16.0% and profit up 51.5% on a year earlier.
- 1 Sep 2026: ex-date for a dividend of ₹5 a share.
What dividend does Alivus Life Sciences pay?
Alivus Life Sciences paid ₹5 a share in regular dividends in the 12 months to 20 November 2026 (1 payment), a yield of 0.35% at the ₹1,436.90 close on 20 November 2026. The last was a dividend of ₹5 a share, ex-date 1 September 2026.
Alivus Life Sciences dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 1 Sep 2026Dividend | ₹5 | Dividend | same day |
| 1 Sep 2025Dividend | ₹5 | Dividend | same day |
| 17 Oct 2023Interim | ₹22.50 | Interim | same day |
| 24 Mar 2023Interim | ₹21 | Interim | same day |
| 15 Sep 2022Dividend | ₹10.50 | Dividend | — |
| 22 Nov 2021Interim | ₹10.50 | Interim | 23 Nov 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Alivus Life Sciences Ltd paid out 11% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 9 reported years.
From the exchange corporate-actions record, read 20 November 2026.
What did Alivus Life Sciences management say on the latest results call?
On the call for July to September 2026, held on 30 October 2026, Alivus Life Sciences' management guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction.
“Accordingly, we reiterate our FY27 revenue growth guidance of 10% to 12%. We are confident of delivering EBITDA margins in the 35% to 36% range in FY27.”Yasir Rawji, on the call for July to September 2026
What management guided
- FY27 operating margin 35-36% guided despite H2 mix dilution from GPL pickup.
- FY28 operating profit aiming similar to FY27 with 30-32% floor if conditions weaken.
- Solapur Phase 1 operational in October to December 2026 as intermediate and backward-integration site progressing as planned.
- CDMO to double in 3-4 years to 12-15% of revenue with at least one new project in H1 next year.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 30 October 2026.
What to watch in Alivus Life Sciences' next results?
When Alivus Life Sciences reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Solapur Phase 1 commissioning against flagged quarter - check operational status, first batches and inspection triggers.
Management raised each of these on the latest results call.
- Solapur Phase 1 commissioning against flagged quarter - check operational status, first batches and inspection triggers.
- GPL volume rebound in H2 and margin within guided band - check pickup pace against dilution commentary.
- CDMO quarterly cadence given lumpiness warning - check annual improvement and new-project closure progress versus volatility.
Which stock lists is Alivus Life Sciences on?
Alivus Life Sciences is on 4 of our India lists: Multibagger study list, Momentum stocks, Small & mid cap stocks and Pharma stocks.
Is Alivus Life Sciences profitable?
Alivus Life Sciences Ltd earned ₹197 Cr of net profit in the Sep 2026 quarter, +51.5% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹564 Cr. The Sep 2026 quarter's profit is 28.9% of that quarter's revenue. The same quarter a year earlier earned ₹130 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
For the full year, FY26 profit was ₹564 Cr (+16.0% on the year before).
Why profit moved: revenue changed +16.0% on a year earlier and the margin moved +8.5 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +26.7% and revenue +8.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Alivus Life Sciences make, and is it growing?
Alivus Life Sciences Ltd reported ₹682 Cr of revenue in the Sep 2026 quarter, +16.0% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. The last full year, FY26, came in at ₹2,552 Cr. The last four reported quarters add to ₹2,684 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. The CDMO versus branded formulations divergence favours a larger CDMO mix if projects convert. Management cites existing projects, new inquiries and planned contracts, while declining to attach a firm revenue forecast. That makes conversion evidence more important than the size of the stated funnel.
A growth rate over several years is not shown, because there are too few years of figures to work one out properly.
FY26 revenue was ₹2,552 Cr, +6.9% on the year before.
Is growth speeding up? Revenue over the last 12 months grew +8.1%, against +10.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +26.2%, against +25.9% a year (stabilising).
Watch next
- Metric
- CDMO funnel conversion
- Threshold
- The planned contracts slip again or existing programmes do not improve in the second half.
- Which result
- the next result
How much of every ₹100 of sales does Alivus Life Sciences keep?
Alivus Life Sciences Ltd's operating margin was 38.9% in the Sep 2026 quarter, 8.5 percentage points higher than the same quarter a year ago. Across 9 years it has been between −4.0% and 31.4%. The latest quarter is above every full year in that period.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. The generic-to-specialty value migration is visible in the latest call: management attributes non-GPL growth to launches and demand across markets. This is the primary operating offset while GPL customers reduce inventory.
Why the margin moved: operating margin changed +8.4 percentage points on the year while gross margin changed +6.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.
Watch next
- Metric
- Non-GPL launch engine
- Threshold
- New launches fail to scale or GPL weakness persists without enough non-GPL growth to cover it.
- Which result
- the next result
Is Alivus Life Sciences' profit turning into cash?
Over the last 3 years, 90% of Alivus Life Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹565 Cr of operating cash against ₹564 Cr of profit. After ₹307 Cr of spending on assets, ₹258 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 90% of profit came in as cash: the cash cycle got 26 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.
What to look at next: the bigger use of cash is spending on new assets, at 3.2× depreciation over three years. The next section checks what that spending is building.
Where does Alivus Life Sciences' cash go?
Alivus Life Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 267 days in FY26, up from 241 days in FY21. It spent ₹602 Cr on assets over the last 3 years. Customers take 153 days to pay, and stock sits for 246 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹2,552 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly ₹1,867 Cr is tied up in the business at any time.
FY26: customers took 153 days to pay and stock sat for 246 days, about 8.1 months of sales sitting as stock, for a full cycle of 267 days, longer than FY21's 241.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 246 days. Customers pay about 153 days after that. Suppliers are paid at 132 days. Together that makes the 267-day cycle.
Spending on assets: ₹602 Cr over the last 3 years, against ₹189 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹284 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Alivus Life Sciences' P/E ratio, and how does it compare with its own history?
Alivus Life Sciences Ltd's P/E is 26.3×, near the high end of its own history: higher than 81% of past readings. Its usual P/E (the middle reading) is 21.2×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹54.57.
Why the multiple is where it is: over the past year earnings per share moved +26.1% while the price moved +59.0%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 5 years the price moved +18.1% a year; about +10.8% a year came from earnings growth and about +7.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
Is the Alivus Life Sciences business getting better or worse?
Alivus Life Sciences Ltd's business is getting better. Profit growth was −15.0% 7 quarters ago and has recovered to +26.2%, with ROCE steady at 26.4% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: a lasting rise from a low is what this page is built to show.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +6.9% | +5.7% | +6.2% | — |
| Profit | +16.0% | +6.5% | +9.9% | — |
| EPS | +16.0% | +6.5% | +7.1% | — |
| Share price | +59.0% | +31.9% | +18.1% | — |
What is the Alivus Life Sciences story, and has it been checked?
Alivus Life Sciences Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: mid expansion. Still open: The thesis breaks if non-GPL growth no longer offsets GPL weakness while operating margin falls below management's stated range and the promised capacity and CDMO milestones slip again.
NOT YET CHECKED
From the price. Price stage 2, week 31, above its 200-day line, relative strength falling.
What is not proven yet. The thesis breaks if non-GPL growth no longer offsets GPL weakness while operating margin falls below management's stated range and the promised capacity and CDMO milestones slip again.
The test written in advance. CDMO contract timing. Measured by: CDMO contract timing Confirmation of the planned new contracts and disclosed CDMO mix in the next result. by the next result.
What the company does. The latest quarter delivered revenue growth and profit growth, with operating margin above the prior-year level as launches, mix and efficiency offset GPL weakness.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters | What to watch |
|---|---|---|---|
| Non-GPL launch engine | HIGH | Non-GPL growth is offsetting GPL inventory rationalization and broadening the revenue base. | New launches fail to scale or GPL weakness persists without enough non-GPL growth to cover it. |
| Mix and process margin bridge | HIGH | Launch mix and operating efficiency have lifted margins above the previous-year quarter. | Raw-material inflation exceeds pass-through and GPL mix normalizes faster than launch economics scale. |
| CDMO funnel conversion | MEDIUM HIGH | Returning programmes and prospective contracts can add higher-value revenue, but the funnel remains timing-sensitive. | The planned contracts slip again or existing programmes do not improve in the second half. |
| Capacity and backward integration | MEDIUM | The planned sites can add regulated-market capacity and lower precursor cost after commissioning. | Commissioning or regulatory inspection slips further, or utilisation remains below the expected ramp. |
Everything further down this page is evidence for or against these.
FY26-Q2FY27-Q1
What the surface reading misses. The surface reading is: Profit growth above revenue growth indicates operating leverage. The research reads it further: The gap is consistent with higher operating margin and management's stated mix and efficiency bridge, not a one-quarter exceptional-item flag in the supplied ledger.
What the surface reading misses. The surface reading is: Margin expansion implies improving economics. The research reads it further: The latest margin is above the mid-cycle margin and management attributes the improvement to mix, launches and efficiency; this supports execution but means current earnings are not trough-depressed.
- 1 · Operating leveragebuilding
- 2 · Value-added mixbuilding
- 3 · Management changequiet
- 4 · Paying down debtquiet
- 5 · Regulatory approvalquiet
- 6 · Order-book winsbuilding
- 7 · Consolidationbuilding
- 8 · Demerger or value unlockquiet
- 9 · Buybackquiet
- 10 · New geographiesquiet
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsquiet
- 16 · Asset qualityquiet
Lever 2 · Value-added mix: building. Non-GPL growth is offsetting GPL inventory rationalization and broadening the revenue base. What proves it keeps working: Non-GPL launch engine. It stops working if New launches fail to scale or GPL weakness persists without enough non-GPL growth to cover it.
Lever 1 · Operating leverage: building. Launch mix and operating efficiency have lifted margins above the previous-year quarter. What proves it keeps working: Mix and process margin bridge. It stops working if Raw-material inflation exceeds pass-through and GPL mix normalizes faster than launch economics scale.
Lever 7 · Consolidation: building. Returning programmes and prospective contracts can add higher-value revenue, but the funnel remains timing-sensitive. What proves it keeps working: CDMO funnel conversion. It stops working if The planned contracts slip again or existing programmes do not improve in the second half.
Lever 6 · Order-book wins: building. The planned sites can add regulated-market capacity and lower precursor cost after commissioning. What proves it keeps working: Capacity and backward integration. It stops working if Commissioning or regulatory inspection slips further, or utilisation remains below the expected ramp.
Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Alivus Life Sciences management deliver what it promised?
What Alivus Life Sciences Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
FY27 EBITDA Margin Guidance Raised Without Reconciliation · 30 October 2026. In Jul 2026 and May 2026, management guided to FY27 EBITDA margins of 30% to 32%, while the Oct 2026 call raised the range to 35% to 36%. Although the latest call cited better revenue mix and operating efficiencies, it did not quantify or reconcile why the prior full-year framework was superseded, creating a material change for earnings estimates.
CDMO Contract Commitments Shifted · 30 October 2026. The May 2026 and Jul 2026 calls pointed to two new CDMO deals in the early part of H2 FY27, with the Jul 2026 discussion still framing the contracts as expected and on track. By Oct 2026, management had reframed the expected closure as the first half of next year and reduced the firm commitment to at least one project, representing a material timing and scope change without an explanation for the slippage.
CDMO Capacity Narrative Reversed · 30 October 2026. In Jul 2026, management broadly said capacity was not a challenge for Alivus and described its facilities as top of the line. In Oct 2026, it acknowledged that the company had not entertained large-volume CDMO opportunities because it lacked capacity, changing the assessment of CDMO growth headroom and requiring clarification of the scope of the earlier statement.
New-Launch Margin Durability Changed · 30 October 2026. Jul 2026 presented the margin benefit from launches as stable and continuing, whereas Oct 2026 said margins on newly launched products have an 18-24-month shelf life before normalizing.
Every quote above is taken word for word from the company’s own earnings calls.
What is Alivus Life Sciences management's track record?
The company keeps internal funding as its stated plan despite delayed spending; that remains a forecast. Prior stress-call summaries carry date mismatches, so they cannot establish a dated delivery record. Streams 1-2 REVEAL the named patent restriction and current GST demand; no material-size misconduct finding is established. Stream 5 returned no matching excerpts.
Regulatory and governance record
Incyte and Vertex patent disputes, the GST demand and the older fire-related pollution notice are named and retained. The excerpts show no proven fraud, lie or adverse misconduct ruling, and do not establish an open case of real financial size under the current verdict bar. The underlying GST grounds and patent exposure remain gaps.
Checked 14 October 2026.
How much does Alivus Life Sciences earn on its capital?
Alivus Life Sciences Ltd earned a ROCE of 24% in FY26. Its return on capital used (ROIC) is 12.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 22.1% net margin and 0.64× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 22.1% net margin × 0.64× asset turnover × 1.20× leverage (assets divided by equity) ≈ 17.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 24.0% − 12.0% = +12.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 24.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 22.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Alivus Life Sciences have too much debt?
Alivus Life Sciences Ltd has total debt of ₹53.0 Cr against shareholder equity of ₹3,632 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Alivus Life Sciences shareholding pattern?
Domestic institutions raised their stake in Alivus Life Sciences Ltd by 2.9 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 7.0% of the company. Foreign institutions moved −1.9 points over the same period, to 5.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Domestic institutions: +2.9 points over 8 quarters, to 7.0%; Foreign institutions: −1.9 points over 8 quarters, to 5.9%; Promoters: −0.2 points over 8 quarters, to 74.8%.
Why the owners changed: foreign institutions moved −1.9 points and domestic institutions +2.9 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.
How far is Alivus Life Sciences from balance-sheet trouble?
For Alivus Life Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Alivus Life Sciences rank in its industry?
63.5 out of 100, rank 2 of 4 in Pharmaceuticals Bulk Drugs & Formulation, with 97% of the evidence available.
Alivus Life Sciences Ltd scores 63.5 out of 100 against the 4 companies it is compared with in Pharmaceuticals Bulk Drugs & Formulation, ranking 2. Earnings are strong; relative strength in its sector is -14.2% and the one-year return is 59%.
The four parts add up to the total exactly: 25.7 + 23 + 9.8 + 5 = 63.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Alivus Life Sciences compared with?
Alivus Life Sciences ranks 2 of 4 Pharmaceuticals Bulk Drugs & Formulation companies on the 4-Factor Sector Score, with 63.5 out of 100.
- 1Anlon Healthcare LtdAHCL · breaking out · Most evidence points up · 74% evidence65.5out of 100
How the score adds up
Growth & earnings 19.3/35 · Revenue 26.9% · Profit 2.8% · Operating margin change -2.3 points · 100% evidenceCapital efficiency 19.2/25 · ROCE 22.4% (year to Mar 2026) · Operating margin 23.9% · 100% evidenceValuation 10.0/20 · P/E 48.4× · PEG — · 0% evidenceRelative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 9% · Strength vs NIFTY 500 (same reading) 57.6% · 1 year 62.3% · 70% evidence · 12 of 12 weeks aheadExact sum: 19.3 + 19.2 + 10 + 17 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 2Alivus Life Sciences Ltd this pageALIVUS · losing its lead · Evidence leans up · 97% evidence63.5out of 100
How the score adds up
Growth & earnings 25.7/35 · Revenue 8.1% · Profit 26.2% · Operating margin change 9 points · 100% evidenceCapital efficiency 23.0/25 · ROCE 23.8% (year to Mar 2026) · Operating margin 38.9% · 100% evidenceValuation 9.8/20 · P/E 26.3× · PEG 1.41 · 85% evidenceRelative strength 5.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -14.2% · Strength vs NIFTY 500 (same reading) 27.5% · 1 year 59% · 100% evidence · 11 of 12 weeks aheadExact sum: 25.7 + 23 + 9.8 + 5 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -14.2% and the one-year return is 59%. - 3Valiant Laboratories LtdVALIANTLAB · breaking out · Evidence leans up · 65% evidence60.6out of 100
How the score adds up
Growth & earnings 33.3/35 · Revenue 100% · Profit 100% · Operating margin change 4.3 points · 100% evidenceCapital efficiency 4.8/25 · ROCE 0.6% (year to Mar 2026) · Operating margin 4.4% · 100% evidenceValuation 10.0/20 · P/E 31.9× · PEG — · 0% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 27.9% · 1 year — · 25% evidence · 7 of 7 weeks aheadExact sum: 33.3 + 4.8 + 10 + 12.5 = 60.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 4Amanta Healthcare LtdAMANTA · leader · Evidence leans up · 74% evidence60.5out of 100
How the score adds up
Growth & earnings 21.2/35 · Revenue 9.9% · Profit 22.5% · Operating margin change 0 points · 100% evidenceCapital efficiency 12.3/25 · ROCE 11.6% (year to Mar 2026) · Operating margin 20.7% · 100% evidenceValuation 10.0/20 · P/E 47.2× · PEG — · 0% evidenceRelative strength 17.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 9.4% · Strength vs NIFTY 500 (same reading) 59.8% · 1 year 90.6% · 70% evidence · 11 of 12 weeks aheadExact sum: 21.2 + 12.3 + 10 + 17 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharmaceuticals Bulk Drugs & Formulation, all 4 compared on one page.
Which companies are close to Alivus Life Sciences in size?
Alivus Life Sciences is the largest of 4 Pharmaceuticals Bulk Drugs & Formulation companies on Sector Alpha by market value (at the 20 November 2026 close). It is the largest. Just below it: Anlon Healthcare, Amanta Healthcare and Valiant Laboratories.
Pharmaceuticals Bulk Drugs & Formulation companies close in size
- Alivus Life Sciences Ltd ₹17,670 crore
- Anlon Healthcare Ltd ₹1,338 crore
- Amanta Healthcare Ltd ₹863 crore
- Valiant Laboratories Ltd ₹515 crore
All 4 Pharmaceuticals Bulk Drugs & Formulation companies, largest first
Companies close in size in other industries
- Lalithaa Jewellery Mart Ltd ₹17,723 crore
- Cohance Lifesciences Ltd ₹17,689 crore · Pharma - API & CRAMS
- Alivus Life Sciences Ltd ₹17,670 crore
- Elgi Equipments Ltd ₹17,648 crore · Compressors
- Pfizer Ltd ₹17,640 crore · Pharma - MNC bulk Drugs
What else do people ask about Alivus Life Sciences?
What is Alivus Life Sciences's share price today?
Alivus Life Sciences Ltd's share price is ₹1,436.90, +59.0% over the past year. The whole company is worth ₹17,665 Cr on the market.
In the last 52 weeks it traded between ₹880 to ₹1,559; today it is 82% of the way up from the low, 19.0% above its 200-day average (as of 20 November 2026).
What were Alivus Life Sciences's latest quarterly results?
Alivus Life Sciences Ltd reported revenue of ₹682 Cr and net profit of ₹197 Cr for the Sep 2026 quarter. Revenue rose 16.0% and profit rose 51.5% compared with a year earlier. Earnings per share were ₹16.03.
The operating margin was 38.9%, 8.5 percentage points higher than a year earlier (as of 20 November 2026).
What is Alivus Life Sciences's market cap?
Alivus Life Sciences Ltd's market capitalisation is ₹17,665 Cr at a share price of ₹1,436.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026).
How is Alivus Life Sciences performing?
Alivus Life Sciences Ltd's share price has been rising for 31 weeks. In its latest quarter, revenue rose 16.0% and profit rose 51.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 26 weeks running (as of 20 November 2026).
Will Alivus Life Sciences's share price go up?
This page does not forecast Alivus Life Sciences Ltd's share price. What it shows instead: the share price is ₹1,436.90, and it has been rising for 31 weeks. Its P/E of 26.3× is higher than 81% of its own last 5 years (as of 20 November 2026).
Who owns Alivus Life Sciences?
Promoters own 74.8% of Alivus Life Sciences Ltd, foreign institutions 5.9%, domestic institutions 7.0% and the public 12.2% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 2.9 percentage points over 8 quarters (as of 20 November 2026).
Where is Alivus Life Sciences in its business cycle?
Alivus Life Sciences Ltd's FY26 operating margin was 31.3%, against a 9-year range of −4.0% to 31.4%. The latest quarter was 38.9%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026).
What could break the Alivus Life Sciences story?
The main question: the share price moved +59.0% in a year while earnings per share (last four quarters) moved +26.1%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026).
Is Alivus Life Sciences a stock worth studying right now?
What the numbers show: Alivus Life Sciences Ltd's share price has risen faster than its earnings: +59.0% in a year, against +26.1% for earnings per share. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026).
Is there a Alivus Life Sciences share price forecast for 2026?
What management itself guided: FY27 revenue growth 10-12% reiterated on H2 strength and launch traction.
Where does this page get Alivus Life Sciences' management information?
From Alivus Life Sciences' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 20 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.